Group 1 - Zheng Yongda has been appointed as the Party Secretary and Chairman of Xiamen International Trade Holdings Group Co., Ltd. [1] - Prior to this role, Zheng Yongda served as the Deputy Secretary and General Manager of Xiamen Jianfa Group Co., Ltd. [3] - The previous Party Secretary and Chairman of Xiamen International Trade Holdings was Xu Xiaoxi, who has now taken on the same roles at Xiamen Jianfa Group [3] Group 2 - Xiamen International Trade Holdings Group is a state-owned enterprise based in Xiamen, focusing on modern, international, and comprehensive capital investment [4] - The company operates in various sectors including supply chain services, urban construction and operation, consumer and health, advanced manufacturing, and financial services [4] - Xiamen International Trade Holdings is recognized as a Fortune Global 500 company and has consistently ranked in various top enterprise lists in China [4]

Group 1 - Lingyun Optics' actual controller promises not to reduce shareholdings for 12 months starting from July 7, 2025 [1] - Chengdi Xiangjiang's subsidiary signed a contract with China Mobile for a data center project worth 1.632 billion yuan, with a 92-day construction period starting April 30, 2025 [1] - Dingyang Technology launched a high-end arbitrary waveform generator with a maximum output frequency of 5 GHz, catering to communication, industrial, and research testing needs [2][3] Group 2 - Heng Rui Medicine completed a share repurchase plan, buying back 12.9051 million shares for 601 million yuan, representing 0.20% of total shares [4][5] - ST Xiangxue received approval for clinical trials of TAEST1901 injection for treating advanced gastric cancer [5] - Yuyue Medical's subsidiary received EU MDR certification for its AED product, valid until May 11, 2030 [6][7] Group 3 - HNA Holding reported a 10.33% year-on-year increase in passenger revenue kilometers for April [8] - Springhui Zhikong's subsidiary terminated its listing on the National Equities Exchange and Quotations [9] - Delin Hai's shareholder plans to reduce holdings by up to 3%, equating to 3.39 million shares [10] Group 4 - Weiye Co. announced that two shareholders plan to reduce their holdings by up to 2% [12] - Green Alliance Technology's major shareholder intends to reduce holdings by up to 3% [14] - Luzhou Development Group increased its stake in Luzhou Tianhua by 1.02%, acquiring 15.9557 million shares [16] Group 5 - Hualan Pharmaceutical's subsidiary plans to acquire a 42.82% stake in Sanjing Qianhe for 23.446 million yuan [17] - Ganfeng Lithium's directors and executives plan to invest 30.8 million yuan in Shenzhen Yichu [19] - Zhonghong Medical's subsidiary is expected to be selected for a centralized procurement project [20] Group 6 - Jinkai Biotechnology's Blue Zone Fund plans to reduce holdings by up to 3% [21] - Hangxin Technology's former controlling shareholder intends to reduce holdings by up to 3% [22] - Galaxy Magnet's director plans to reduce holdings by up to 0.79% [23] Group 7 - Zhuoyue Technology's controlling shareholder's shares will be auctioned due to judicial proceedings [24] - Xinwufeng is forming a joint venture with France's Coplison Group with a registered capital of 80 million yuan [25] - Zhongcheng Co. is planning to issue shares to acquire 100% of a clean energy company, leading to a temporary stock suspension [26][27]

Core Viewpoint - Zhonghong Medical's subsidiary, Kelong Medical, is set to be selected for the volume-based procurement project for medical consumables in the central region of Xinjiang Uygur Autonomous Region, which will prioritize the use of its products in local medical institutions [1] Group 1 - Zhonghong Medical announced that Kelong Medical participated in the second batch of volume-based procurement for medical consumables in the central alliance of Xinjiang Uygur Autonomous Region [1] - The selected products include disposable vacuum blood collection tubes and disposable venous blood sampling needles [1] - During the procurement period, medical institutions in the procurement area will give priority to using the products proposed for selection by the company [1]

一、拟中选产品基本情况 证券代码：300981 证券简称：中红医疗 公告编号：2025-040 中红普林医疗用品股份有限公司 关于子公司参与集中带量采购项目拟中选的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 中红普林医疗用品股份有限公司（以下简称"公司"）控股子公司江西科伦 医疗器械制造有限公司（以下简称"科伦医械"）于近期参加新疆维吾尔自治区 中部联盟（第二批）医用耗材带量联动采购项目的投标工作。根据新疆维吾尔自 治区中部联盟（第二批）医用耗材带量联动采购中选结果显示，科伦医械部分产 品拟中选上述集中带量采购项目。现将相关情况公告如下： | 采购产品 | 产品分组 | 规格型号 | 注册证号 | 注册分类 | 适用范围 | 拟中选价 | 拟供应 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 格及数量 | 地区 | | | | 2ml、3ml、4ml、 | | | | | | | | 血清管（橘 | 5ml、10ml 血清管 | | | | | | | | 红色/红 ...

Group 1: Company Performance and Financials - In 2024, the company achieved a revenue of 245,665.07 million CNY, with a net profit of -8,712.89 million CNY [7] - In Q1 2025, the company reported a revenue of 62,915.00 million CNY and a net profit of 1,892.11 million CNY [7] Group 2: Growth Drivers - The main growth drivers include the expanding market for medical devices due to rising health awareness and consumption levels [3] - The company is enhancing its product matrix, maintaining a leading position in disposable nitrile gloves and increasing the proportion of high-margin products [3] - Continuous improvement in both domestic and international sales capabilities is expected to support future performance [3] Group 3: Industry Outlook - The medical device industry is anticipated to grow due to the exit of outdated production capacities and stable global demand [4] - The global healthcare market is projected to maintain stable growth, supported by national strategies prioritizing healthcare technology [8] Group 4: Strategic Initiatives - The company plans to focus on R&D, market expansion, quality assurance, and cost reduction to improve profitability [6] - There is an ongoing effort to explore mergers and acquisitions to enhance growth and optimize product structure [6] Group 5: Challenges and Market Sentiment - The company's stock has been trading below its issue price and net asset value, with three consecutive years of losses [6] - Market sentiment, industry dynamics, and operational performance are influencing the stock price [6]

北京德恒律师事务所 关于中红普林医疗用品股份有限公司 2024 年年度股东大会的 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话:010-52682888 传真:010-52682999 邮编:100033 北京德恒律师事务所 关于中红普林医疗用品股份有限公司 2024 年年度股东大会的法律意见 （三）公司于2025年4月23日在巨潮资讯网（http://www.cninfo.com.cn） 公布的《中红普林医疗用品股份有限公司关于召开 2024 年年度股东大会的通知》 （以下简称"《股东大会的通知》"）； 北京德恒律师事务所 关于中红普林医疗用品股份有限公司 2024 年年度股东大会的 法律意见 德恒 01G20250295-01 号 致：中红普林医疗用品股份有限公司 中红普林医疗用品股份有限公司（以下简称"公司"）2024 年年度股东大 会（以下简称"本次会议"）于 2025 年 5 月 14 日（星期三）召开。北京德恒律 师事务所（以下简称"德恒"）受公司委托，指派吴莲花律师、廖齐越律师（以 下简称"德恒律师"），根据《中华人民共和国证券法》（以下简称"《证券法》"）、 《中华人 ...

证券代码：300981 证券简称：中红医疗 公告编号：2025-039 中红普林医疗用品股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1. 本次股东大会没有出现否决提案的情形。 2. 本次股东大会不涉及变更以往股东大会已通过决议的情形。 一、会议召开情况和出席情况 1. 会议召开时间： 现场会议召开时间：2025 年 5 月 14 日（星期三）14:30； 网络投票时间：2025 年 5 月 14 日。其中，通过深交所交易系统进行网络投 票的时间为 2025 年 5 月 14 日 9:15－9:25，9:30－11:30 和 13:00－15:00；通 过深圳证券交易所互联网系统投票的具体时间为2025年5月14日9:15－15:00。 2. 现场会议召开地点：北京经济技术开发区科创六街 87 号四楼会议室。 3. 会议召开方式：现场表决与网络投票相结合的方式。 4. 会议召集人：公司董事会。 5. 会议主持人：董事长桑树军先生。 6. 本次股东大会的召集及召开符合《中华人民共和国公司法》《中红普林 ...

证券代码：300981 证券简称：中红医疗 公告编号：2025-038 中红普林医疗用品股份有限公司 关于更换持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 中红普林医疗用品股份有限公司 董事会 中红普林医疗用品股份有限公司（以下简称"公司"）于近日收到公司首次 公开发行股票并在创业板上市的保荐机构国泰海通证券股份有限公司（以下简称 "国泰海通证券"）出具的《国泰海通证券股份有限公司关于更换中红普林医疗 用品股份有限公司持续督导保荐代表人的函》，国泰海通证券原委派张子慧先生、 雷浩先生为公司 IPO 项目保荐代表人，负责保荐工作及持续督导工作。由于原保 荐代表人张子慧先生因工作安排原因，无法继续从事公司的持续督导工作，为保 证持续督导工作的有序进行，国泰海通证券现委派保荐代表人邓伟先生接替张子 慧先生继续履行持续督导工作，保荐代表人邓伟先生简历详见附件。邓伟先生将 接替张子慧先生作为国泰海通证券保荐代表人，参加公司于 2025 年 5 月 15 日 (星期四)15:00-16:00 举办的 2024 年度暨 2025 年第一季度业绩说 ...

证券代码：300981 证券简称：中红医疗 公告编号：2025-037 中红普林医疗用品股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 中红普林医疗用品股份有限公司（以下简称"公司"）分别于 2024 年 12 月 9 日、2024 年 12 月 25 日召开第四届董事会第四次会议及第四届监事会第四次会 议、2024 年第三次临时股东大会，审议通过了《关于公司及子公司 2025 年度向 银行申请综合授信额度暨公司为子公司申请综合授信额度提供担保的议案》，同 意公司为控股子公司 2025 年度向金融机构申请的授信额度提供担保，其中，为 资产负债率 70%（含）以上的控股子公司提供担保额度为不超过 15 亿元，为资 产负债率低于 70%的控股子公司提供担保额度为不超过 10 亿元，担保额度总计 不超过 25 亿元。具体内容详见《关于公司及子公司 2025 年度向银行申请综合授 信额度暨公司为子公司申请综合授信额度提供担保的公告》（公告编号：2024- 083）。 二、担保进展情况 7. 经营范围：生产 ...

中红医疗（300981）公告，子公司江西科伦医疗器械制造有限公司近期取得国家药品监督管理局颁发的 《医疗器械变更注册(备案)文件》。此次变更涉及一次性使用输液用肝素帽，注册分类为Ⅲ类，变更内 容为产品技术要求。本文件与原注册证共同使用。上述注册证变更是在原有基础上进行的相应变更，对 公司未来业绩的影响尚无法预测。 ...